Abstract 2056P
Background
The wider availability of oncological treatment and the improved survival of cancer patients have increased the frequency of emergency consultations and their impact on healthcare. The aim of this study was to investigate the variables that influence hospital admission, re-consultation and clinical outcomes among oncology patients who seek emergency care.
Methods
Single-center, observational and prospective study. We analyzed a sample of 554 oncology patients who consulted in the Emergency Deparment during regular office hours between March-22 and March-23. Statistics: Chi-squared test to assess association between variables. Kaplan-Meier curves and log-rank test for survival analysis. Significance level: p-value <=0.05.
Results
The baseline characteristics of the study participants were: 50.2% females, 21.5% lung cancer, 68.8% stage IV, 25.8% consulted for digestive symptoms, 37% were hospitalized and 16.4% reconsulted in the following 15 days. The overall median survival was 54 weeks. Factors that were associated with a higher likelihood of hospitalization were lung cancer (26.9% of admissions), stage IV (80.7%), monotherapy chemotherapy (CT) (36.3%), first-line treatment for metastatic disease (40.9%), ECOG 2 (36.8%), digestive symptoms as reason for consultation (29.2%) and complications secondary to the tumor itself as definitive diagnosis (32.2%). Factors significantly associated with a higher likelihood of reconsultation within the following 15 days were lung cancer (19.3% of reconsultations), monotherapy CT (38.6%), ECOG 1 (42.1%) and infectious pathology and complications secondary to the tumor itself (28.1% each one). Factors significantly associated with lower overall survival were hospital admission (median: 16 weeks, 95% CI 3.7-28.2), diagnosis of complications secondary to the tumor itself (median: 11 weeks, 95% CI 10.3 - 23.6) and reconsultation (median: 17 weeks, 95% CI 10.3-23.6).
Conclusions
Among oncology patients admitted to the Emergency department, complications secondary to the underlying oncological disease represent the most relevant variable in the field of oncological emergencies due to their impact on the likelihood of hospitalization, reconsultation and survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Sanofi, Lundbeck, Angelini. M.A. Ivars: Financial Interests, Personal, Speaker, Consultant, Advisor: Ipsen Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06